The higher frequency of gastrointestinal side effects also observed with efinopegutide in Phase 2 trials may also be explained by a relatively high receptor potency of at GCGR and GLP-1R, within 3-fold of the native ligands (81)
As its full safety profile remains under investigation, the following reflects current available data and known class effects: Gastrointestinal symptoms are the most common: nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation
Dispersible tablets may be preferred by users who want a quick-mixing supplement option
Talk to your healthcare provider about safe and effective alternatives to semaglutide if you are looking for an OTC option
HHS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations in Continued Effort to Lower Prescription Drug Costs for Seniors, CMS, 2025
Conclusion The FDA's ruling on Semaglutide, effective as of April 7, 2025, poses significant changes for aesthetics practices, requiring a shift to branded medications by mid-2025, subject to legal outcomes
